Recruiting
Early Phase 1

Rho-Kinase Inhibitor

Sponsor:

University of the Incarnate Word

Code:

NCT04234932

Conditions

Glaucoma, Open-Angle

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Netarsudil Ophthalmic

Study Details

Brief summary:

Investigate changes in optical coherence tomography angiography of the optic nerve and macula following topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution.

Conditions

Glaucoma, Open-Angle

Study ID

NCT04234932

Start date

Jan 6, 2020

Status verified date

Apr, 2020

Completion date

Jan, 2021

Anticipated

Primary completion date

Jan, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Normal ocular health

Exclusion Criteria:

  • Females who are or may be pregnant or who are nursing
  • Uncontrolled hypertension
  • Allergy to netarsudil or latanoprost

Study Design

Enrollment

10 participants

Anticipated

Allocation

Randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Netarsudil alone

Topical application of netarsudil 0.02%

active comparator: Netarsudil plus latanoprost

Topical application of netarsudil 0.02% with latanoprost 0.005%

Interventions

Netarsudil Ophthalmic

Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)

Primary outcome measure

  • Peripapillary capillary perfusion density [ Time Frame: 90 minutes ]

Central Contacts and Locations

Central contacts

Mary Jo Bilicek

210-805-3565bilicek@uiwtx.edu

Locations

University of the Incarnate Word

Recruiting

San Antonio, Texas, United States, 78209

Contacts

Ana C Hagendorf, PhD

210-805-3036wandless@uiwtx.edu

More Information

Sponsor

University of the Incarnate Word

Last update posted

Apr 14, 2020

Last verified

Apr, 2020

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of the Incarnate Word on 2020-04-14.